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SObjective: Pneumonectomy after neoadjuvant therapy remains controversial.
Methods: A systematic PubMed search was performed for original articles from 1990 through 2010 describing
pneumonectomy after neoadjuvant therapy. Specific data on 30-day and 90-day perioperative mortalities were
abstracted from these articles. Meta-analysis compared 30-day mortality between right and left pneumonectomy
with a fixed-effects model. Comparison between 30-day and 90-day mortalities was also performed.
Results: The search strategy yielded 27 studies. Overall, 30-day and 90-day perioperative mortalities were 7%
and 12%, respectively. Among 15 studies providing side-specific 30-day mortality, cumulative mortalities were
11% and 5% for right and left pneumonectomies, respectively. In the meta-analysis that included 10 studies, 30-
day mortality for right pneumonectomy remained greater than for left pneumonectomy (odds ratio, 1.97; 95%
confidence interval, 1.11–3.49; P¼ .02). Among 6 studies providing side-specific 90-day mortality, cumulative
mortalities were 20% and 9% for right and left pneumonectomies, respectively. In the meta-analysis that in-
cluded 4 studies, 90-day mortality for right pneumonectomy was greater than for left pneumonectomy (odds
ratio, 2.01; 95% confidence interval, 1.09–3.72; P ¼ .03). Among 11 studies providing both 30-day and
90-day mortalities, mortality difference was 5% (95% confidence interval, 4%–7%, P<.0001). Pulmonary
complications were the most common cause of 30-day and 90-day deaths.
Conclusions: Right pneumonectomy is associated with significantly higher 30-day and 90-day mortalities after
neoadjuvant therapy than left pneumonectomy. Also, 90-day mortality for all pneumonectomies appears to be
greater than expected, suggesting that the 30-day mortality figure may inadequately assess the perioperative
mortality. (J Thorac Cardiovasc Surg 2012;143:55-63)Earn CME credits at
http://cme.ctsnetjournals.org
Pneumonectomy has been associated with increased mor-
bidity and mortality relative to other pulmonary resections.1
In particular, the mortality for pneumonectomy after neoad-
juvant therapy has been thought by some to be prohibitively
high.2 Reports with alarmingly high mortality (>20%),
however, have been countered by other reports with very
low mortality (<5%). This leaves unclear the correct ap-
proach for a patient with preoperatively identified N2 dis-
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The Journal of Thoracic and Csituation involves a large central tumor, which may limit
the dose of radiotherapy that can be safely given, also mak-
ing the alternative of definitive chemoradiation less appeal-
ing. Particularly for young patients, in whom the risk of
surgical mortality in general is low, it is unclear whether
the mortality after neoadjuvant therapy and pneumonec-
tomy is in fact low enough to justify this approach.
The main hypothesis is that the published literature does
not support the notion that all pneumonectomies after neo-
adjuvant therapy are categorically associated with high
perioperative mortalities. The primary objective was to
demonstrate that right pneumonectomy and not left pneu-
monectomy in particular is associated with a significantly
higher perioperative mortality. The secondary objectives
of this review were (1) to determine whether 30-day mortal-
ity is different from 90-day mortality and (2) to determine
which perioperative complications contribute to periopera-
tive mortality.MATERIALS AND METHODS
The Preferred Reporting Items for Systematic reviews and Meta-
analysis (PRISMA) guidelines were followed as closely as possible for
this systematic review. At the time of the writing of this article, there
was no known review protocol specific to the objectives outlined
previously.ardiovascular Surgery c Volume 143, Number 1 55
Abbreviation and Acronym
PRISMA ¼ Preferred Reporting Items for
Systematic reviews andMeta-analysis
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A comprehensive English-language literature search was performed
with the PubMed database to identify published articles (including articles
in press and those published exclusively electronically) reporting pulmo-
nary resections after neoadjuvant chemotherapy or chemoradiation ther-
apy between January 1, 1990, and April 30, 2010. A Boolean search
strategy was used with the search terms ‘‘non–small cell lung cancer’’
and ‘‘pneumonectomy,’’ ‘‘induction,’’ and ‘‘neoadjuvant.’’ Publications
were included if they met the following criteria: (1) they included more
than 20 patients who underwent pneumonectomy after neoadjuvant che-
motherapy or chemoradiation therapy, (2) they reported the indication
for resection was non–small cell lung cancer, and (3) they reported specific
perioperative mortality. Publications were excluded for any of the follow-
ing reasons: (1) central focus of the study on carinal or sleeve pneumonec-
tomy, (2) central focus of the study on extrapleural pneumonectomy, (3)
indication for pneumonectomy for disease processes other than non–small
cell lung cancer (eg, mesothelioma, small cell lung cancer, or metastatic
disease), (4) not more than 20 pneumonectomies, or (5) lack of
pneumonectomy-specific data, particularly resection-specific periopera-
tive mortality. Extended pneumonectomies (eg, with pericardial, great ves-
sel, or chest wall resection) were included as long as they did not include
carinal or sleeve pneumonectomies. The search further excluded case re-
ports and reviews. Studies from authors or institutions that reported a series
that expanded on an earlier series were included; however, the earlier se-
ries were not included in these cases. Studies were not excluded on the ba-
sis of the type of chemotherapy or chemoradiation therapy regimens that
were used.
Data Abstracted
Specific data that were collected included the period of time in which
the patients were either accrued or studied, number of institutions, method
of staging, percentage of patients with stage III disease, and the use of neo-
adjuvant chemotherapy or chemoradiation therapy, including the regimens
and doses. The total number of pneumonectomies, the overall 30-day and
90-daymortalities, and the distributions according to the laterality of resec-
tion (when available) were also recorded. In the analysis for this review, the
30-day mortality figures actually reflected publications that reported mor-
tality with a specific 30-day period and those reported as any in-hospital
mortality. We were not able to separate further in-hospital mortality from
30-day mortality, because that information generally was not provided.
All the articles included in this study were thoroughly reviewed, and the
mortalities included reflect either explicit mortality figures that were re-
ported, mortality figures that were calculated from the information pro-
vided in the articles not explicitly reporting mortality, or mortality
figures abstracted from the discussion of the article if mortality was pre-
sented at a meeting but not listed in the original article. If the mortality
was neither provided nor calculable on the basis of the existing informa-
tion, it could not be factored into the analysis. Each article was reviewed
several times to ensure that data were neither missed nor erroneously
labeled.
Complications that caused or contributed to perioperative mortality
were also abstracted and analyzed. The incidence of complications in gen-
eral was not included, because the definitions and diligence of reporting
were highly variable. Complications associated with perioperative death
were grouped into 4 broad categories: pulmonary, infectious, cardiac,
and other. Pulmonary complications were those complications that56 The Journal of Thoracic and Cardiovascular Surgeincluded pneumonia, acute respiratory distress syndrome, and atelectasis
requiring bronchoscopic intervention. The infectious category comprised
bronchopleural fistula and empyema complications. Pneumonia was
grouped with pulmonary complications primarily because this is how it
was reported in many of the articles. Furthermore, distinguishing actual
pneumonia from acute respiratory distress syndrome was not always pos-
sible because the distinction was not immediately clear, and often antibi-
otics are given empirically for patients with acute respiratory distress
syndrome. Cardiac complications consisted of cardiac arrhythmias, heart
failure, myocardial infarction, and other cardiac issues. The ‘‘other’’ com-
plications included gastrointestinal complications, recurrent laryngeal
nerve injury, bleeding or hemothorax, wound issues, and a variety of other
nonspecific issues. Venous thromboembolic complications, including pul-
monary embolism, were also grouped in this category.
Assessments of Study Quality and Publication Bias
Because quality scoring in any systematic review or meta-analysis for
observational studies is controversial,3-5 an internally developed 6-point
criteria system was developed to assess quality. The criteria selected
were based on clinical factors believed to be associated with improved out-
comes and consisted of data that were consistently identifiable as being in-
cluded or not included in each study. These criteria included the following:
size of study, duration of study, era of study, performance in a multicenter
paradigm, inclusion of more than half of the patients with stage III disease,
and the use of invasive staging. The median duration in years (<8 years or
8 years) was used to determine whether the study was long or not long.
Studies published after and including 1994 or before 1994 were considered
later or earlier studies, respectively. The median number of patients in-
cluded among all the studies (<68 or68) was used to dichotomize studies
as large or not large. The numbers of institutions involved were grouped
into 1 versus more than 1, on the basis of speculation that this difference
would be more revealing than a threshold of a given number of multiple in-
stitutions (eg, 4 vs 5). Performance of invasive mediastinal staging rou-
tinely in all of the patients versus in some or an unknown number of
patients was used to dichotomize the studies.
To be considered highest quality or high quality, at least 4 or 2, respec-
tively, of the 6 criteria had to be met. Any study with no criteria or 1 crite-
rion was considered to be low quality and was excluded from the analysis.
Subgroup analyses of 30-day mortality between highest-quality and high-
quality studies were performed. If a significant difference was found
between highest-quality and high-quality studies, then the Woolf method
(inverse variance method) was used for a fixed-effects analysis and the
DerSimonian-Laird method was used for a random-effects analysis. The
selected studies were further categorized according to the design of the
study, and the subset analyses were performed within each design type.
The test of heterogeneity in results across studies was carried out with Hig-
gins I2, which measures the percentage of total variation across the studies.
Publication bias was assessed with Begg funnel plots and Egger tests. If the
funnel plot was asymmetric or the P value was less than .05 by Egger test,
then a publication bias was assigned.
Statistical Analysis of 30-Day Perioperative
Mortality
The pneumonectomy-specific data were analyzed by a meta-analysis
that used a fixed-effects model to compare the 30-day mortality figures be-
tween left and right pneumonectomies and to compare 30-day and 90-day
mortalities. Statistical analysis was performed with the statistical package
R, version 2.10.1.6
Study Control
Therewas no formal funding source for this study.We as the authors had
complete control of the search, data analysis, and writing. No other individ-
uals were involved.ry c January 2012
FIGURE 1. Publication search. Publications were initially identified with a PubMed search that used the terms ‘‘non–small cell lung cancer’’ with ‘‘pneu-
monectomy,’’ ‘‘induction,’’ and ‘‘neoadjuvant.’’ The 315 publications identified were then filtered by a review of the titles, abstracts, and publications to
yield 40 eligible publications. These 40 publicationswere reviewed fully for content, and ultimately 27 studies were included for qualitative analysis. Further
refined numbers of studies were included for the various quantitative analyses.
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Results of Search
The search strategy identified 315 articles (Figure 1). The
individual articles were selected on the basis of year of pub-
lication but without regard to the dates of the operations de-
scribed in the methods and results sections. After screening
of the titles and, when appropriate, the abstracts or actual ar-
ticles, 40 articles were selected for full review. Nine studies
were excluded because neither 30-day nor 90-day
pneumonectomy-specific mortality was reported.7-15 Of the
remaining 31 articles, that matched the selection criteria, 3
additional studies were excluded because of their
redundant nature. The patients in 1 study16 were also in-
cluded in a later article involving a substantially greater num-
ber of pneumonectomies. Two other articles17,18 were
excluded for redundancy because they reported previously
published work and were not as comprehensive in the
desired data as the original articles.19,20 One included
study21 involved a few sleeve pneumonectomies that could
not be separated from the data reported; however, this articles
was still included in the analysis because of the relatively
small number of sleeve pneumonectomies,8 which repre-
sented 10%of the pneumonectomies performed in that study.
There was 1 articles that included only 90-day mortality.22
Ultimately, there were 27 articles that were used for
the analysis (Table 1). Of these 27 articles, 7 were pro-
spective studies2,19,23-27 and 20 were retrospective
studies.15,16,20-22,28-44 Of the 7 prospective trials, 4The Journal of Thoracic and Cwere randomized controlled trials2,19,24,27 and 3 were
cohort studies.23,25,26 Of the 20 retrospective studies, 8
were cohort studies39-40,42-45 and 12 were descriptive
studies.16,18,20,28-30,32-34,36-38,41,46
Study Quality
The 27 studies selected for this review were grouped
into 3 subgroups: randomized controlled trials (prospec-
tive), cohort studies (prospective and retrospective), and
descriptive studies (retrospective). Within these sub-
groups, the quality of each study was graded on the
investigator-derived 6-point scoring system (Table 2). As
would be expected, 3 of the 4 randomized controlled trials
were of the highest quality. Among the cohort and descrip-
tive studies, there were 1 of 11 and 2 of 12 studies that
were of the highest quality, respectively. Study quality
did not significantly affect either the 30-day mortality or
the 90-day mortality.
Publication Bias and Heterogeneity
Funnel plots generated for each of the subgroups dem-
onstrated that there was no significant publication bias
among studies reporting increased 30-day and 90-day
mortalities for right-sided relative to left-sided pneumo-
nectomy or increased 90-day mortality relative to 30-
day mortality (Figure 2). There were 15 studies reporting
side-specific 30-day mortality, with 5 being excluded
from the 30-day funnel plots. There were 6 studiesardiovascular Surgery c Volume 143, Number 1 57
TABLE 1. Summary of characteristics of studies of pneumonectomy after neoadjuvant therapy
Study Period
No. of
sites
Invasively
staged
Clinical stage
III (%) RT
Dose
(Gy)
Total patients (no.) 30-d mortality (no.)
All Right Left All Right Left
Prospective randomized, controlled trials
Albain2 1994–2001 Multiple All 100 Yes 45 54 29 25 14 (26%) 11 (38%) 3 (10%)
Van Schil17,19 1994–2002 Multiple All 100 No — 69* 35 33 5 (7%) 2 (6%) 3 (9%)
Thomas27 1995–2003 Multiple All 100 Some 54 HF 104 39 65 10 (10%) — —
Gilligan24 1997–2005 Multiple Some 8 No — 59 — — 3 (5%) — —
Prospective cohort
Pezzetta26 1994–2003 Single All 100 Yes 44 HF 34 19 15 0 0 0
Lorent25 1995–1998 Single All 100 No — 31 — — 0 — —
Garrido23 1999–2003 Multiple All 10 No — 37 20 17 7 (19%) 6 (30%) 1 (6%)
Retrospective cohort
D’Amato31 1989–2004 Dual Unknown Unknown No — 68 37 31 14 (21%) — —
Gaissert35 1993–2007 Single All 93 Yes 42–72 46 22 24 2 (4%) 1 (4%) 1 (4%)
Gudbjartsson39 1996–2003 Single All 88 Yes 44 35 16 19 0 0 0
Leo44 1998–2005 Single Some 53 No — 99 52 47 3 (3%) — —
Mansour40 1999–2007 Single Unknown Unknown No — 60 29 31 4 (7%) 2 (7%) 2 (6%)
Refai43 2000–2007 Single Some Unknown Some Unknown 102y — — 6 (6%) — —
Stefani21 2001–2007 Single Some 100 No — 79z — — 6 (8%) — —
Brouchet42 2002–2004 Multiple Unknown Unknown No — 195 — — 8 (4%) — —
Descriptive
Kim32 1983–2007 Single Some 95 Yes 40–45 129 65 64 8 (6%)x 6 (9%) 2 (3%)
Doddoli16,46 1989–2003 Single Some 98 Some 30–45 100 55 45 12 (12%) 9 (16%) 3 (7%)
Daly30 1990–2005 Single Some 63 Yes 59 30 18 12 4 (13%) 1 (6%) 3 (25%)
Carretta33 1991–2005 Single Some 100 No — 30 — — 1 (3%) — —
Stamatis34 1991–2002 Multiple All 100 Yes 45 133 — — 9 (7%) — —
Venuta28 1992–2006 Single All 100 Some 40–50 32 18 14 4 (12%) 3 (17%) 1 (7%)
Thibout29 1993–2006 Multiple Some 45 No — 228 117 111 11 (5%) — —
Martin18,20 1993–1999 Single Some 70 Some 10–72 97 46 51 6 (6%) 6 (13%) 0
Perrot36 1993–2002 Single Some 79 No — 55 27 28 1 (2%) 1 (4%) 0
Krasna38 1995–2005 Single Unknown 96 Yes 61 29 15 14 0 0 0
Allen37 1995–2005 Single Unknown 88 Some 54 73 28 45 4 (6%) — —
Alifano41 2000–2006 Single Some Unknown No — 118 54 64 7 (6%) 4 (7%) 3 (5%)
All the studies listed used platinum-based chemotherapy. RT, Radiation therapy; HF, hyperfractionated. *Unknown laterality in 1 case. yTotal number from which analysis per-
formed was 77. zIncludes 10 tracheal pneumonectomies. xNot published, but known to authors.
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cluded from the 90-day mortality funnel plots. The stud-
ies were excluded because either the total mortality, the
right-sided mortality, or the left-sided mortality was
0%. In these studies, the individual odds ratio and vari-
ance for each study would both be infinity. In the meta-
analysis, the weight associated with each study was 0,
and these studies therefore would not contribute to the fi-
nal estimate of odds ratio. The test for heterogeneity
demonstrated that there was no substantial heterogeneity
among the groups and subgroups when evaluated in
terms of 30-day and 90-day mortalities for right versus
left pneumonectomy or increased 90-day mortality rela-
tive to 30-day mortality.
Right Versus Left Pneumonectomy
Perioperative mortality at 30 days. The overall 30-day
mortality among the 27 studies was 7% (Table 2).
Among the 15 studies reporting side-specific 30-day58 The Journal of Thoracic and Cardiovascular Surgemortality, the cumulative mortalities were 11% and
5% for right and left pneumonectomies, respectively
(Figure 3). In the meta-analysis of 10 studies, the
odds ratio of the 30-day mortality (right vs left pneumo-
nectomy) was 1.97 (95% confidence interval, 1.11–
3.49). This effect was statistically significant
(P ¼ .02). No significant heterogeneity results were
found (I2 ¼ 0.7%).
Perioperative mortality at 90 days. The overall 90-day
mortality among the 27 studies was 12%. Among the
6 studies reporting side-specific 90-day mortality, the
cumulative mortalities were 20% and 9% for right
and left pneumonectomies, respectively (Figure 3). In
the meta-analysis of 4 studies, the odds ratio for
90-day mortality for right pneumonectomy vs left pneu-
monectomy was 2.01 (95% confidence interval,
1.09–3.72). This effect was statistically significant
(P ¼ .03). No significant heterogeneity results was
found (I2 ¼ 0.7%).ry c January 2012
TABLE 2. Assessment of study quality
Reference
Long study
period
Later
study era
Large study
size
Multiple
sites
Used invasive
staging
>50% clinical
stage III
Cumulative
quality rank
Prospective randomized controlled trials
Albain2 No Yes No Yes Yes Yes Highest
Van Schil17,19 Yes Yes Yes Yes Yes Yes Highest
Thomas27 Yes Yes Yes Yes Yes Yes Highest
Gilligan24 Yes Yes No Yes No No High
Prospective cohort
Pezzetta26 Yes Yes No No Yes Yes Highest
Lorent25 No Yes No No Yes Yes High
Garrido23 No Yes No Yes Yes No High
Retrospective cohort
D’Amato31 Yes No Yes Yes No No High
Gaissert35 Yes No No No Yes Yes High
Gudbjartsson39 No Yes No No Yes Yes High
Leo44 No Yes Yes No No Yes High
Mansour40 Yes Yes No No No No High
Refai43 No Yes Yes No No No High
Stefani21 No Yes Yes No No Yes High
Brouchet42 No Yes Yes Yes No No High
Descriptive
Kim32 Yes No Yes No No Yes High
Doddoli16,46 Yes No Yes No No Yes High
Daly30 Yes No No No No Yes High
Carretta33 Yes No No No No Yes High
Stamatis34 Yes No Yes Yes Yes Yes Highest
Venuta28 Yes No No No Yes Yes High
Thibout29 Yes No Yes Yes No No High
Martin18,20 No No Yes No No Yes High
Perrot36 Yes No No No No Yes High
Krasna38 Yes Yes No No No Yes High
Allen37 Yes Yes Yes No No Yes Highest
Alifano41 No Yes Yes No No No High
The median number of years (<8 or8) was used to determinewhether the study was long or not long. Studies published after and including 1994 or before 1994 were considered
later or earlier studies, respectively. The median number of patients included among all the studies (<68 or68) was used to dichotomize studies as large or not large. The number
of institutions involved were grouped into 1 versus more than 1 because of speculation that this difference would be more revealing than a threshold of a given number of multiple
institutions (eg, 4 vs5). Performance of invasive mediastinal staging routinely in all the patients versus in some or an unknown number of patients was used to dichotomize the
studies.
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SDifference Between 30-Day and 90-Day
Perioperative Mortalities
Both 30-day and 90-day mortality data were reported in
11 studies; the other 16 provided only one set of data or
the other. These 11 studies were thought to provide
a more accurate comparison of 30 and 90-day mortalities
(Table 3). From these 11 studies, the 90-day mortality
was apparently significantly higher than the 30-day mortal-
ity (difference, 5%; 95% confidence interval, 4.0%–6.8%;
P<.0001, I2¼ 0). Among these studies, increases from 30-
day to 90-daymortality were statistically significant on both
the right side (9%; P ¼ .0001) and the left side (7%;
P ¼ .001).
Effect of Radiation Therapy
The use of radiation therapy was not associated with any
increases in 30-day or 90-day mortality. A lack of anyThe Journal of Thoracic and Csignificant findings was observed when comparing studies
that routinely used radiation with those that either used it
sometimes or never described its use, as well as when the
latter 2 groups were combined (routinely vs sometimes
and never).Causes of Perioperative Mortality
Information regarding cause of 30-day mortality after
pneumonectomy after neoadjuvant therapy were pro-
vided in 11 studies (1 prospective2 and 10 retrospec-
tive16,30-32,34,35,37,41,44,47). Half of the perioperative
deaths were caused by a pulmonary complication
(Figure 4), with the other categories divided approxi-
mately equally. There were only 7 studies that reported
details of the causes of 90-day mortality.16,22,26,29,32,37,38
Pulmonary complications still accounted for the mostardiovascular Surgery c Volume 143, Number 1 59
FIGURE 2. Assessment of publication bias.With Begg funnel plots and Egger tests, a quantitative assessment of publication bias was performed for 30-day
mortality between right-sided and left-sided pneumonectomies (A), 90-day mortality between right-sided and left-sided pneumonectomies (B), and 30-day
mortality versus 90-day mortality (C).
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category. In addition, there were more infections com-
plications as a cause of 90-day mortality than of 30-
day mortality (24% vs 14%; P ¼ .012).DISCUSSION
Impact of Laterality of Resection
A specific focus of this review was exploring the answer
to the question of whether a right pneumonectomy after
neoadjuvant therapy justified or to be avoided. The Inter-
group 0139 trial2 promoted concern about right pneumo-
nectomy, because an (unplanned) subgroup analysis
suggested that the observed 38% 30-day mortality more
than offset any benefit that might have resulted from adding
surgery to the therapeutic strategy. The results of this meta-
analysis suggest that right pneumonectomy is, in fact, asso-
ciated with an increased risk of perioperativemortality. This
study was not one in which the risk factors for perioperativeFIGURE 3. Perioperative mortality. Perioperative mortality represented
according to overall, right, and left pneumonectomies for all 27 studies.
60 The Journal of Thoracic and Cardiovascular Surgedeath associated with neoadjuvant therapy and pneumonec-
tomy were examined, however, and it is therefore impossi-
ble to know the actual reason for this increased risk.
It appears that a left pneumonectomy after neoadjuvant
therapy can be justified from the standpoint of either
30- or 90-day mortality. Of course, the patients must be
assessed for suitability for surgery, and it remains contro-
versial whether surgery should be included in the treatment
strategy for patients with N2 node involvement.
On the other hand, whether a right pneumonectomy is
wise is less clear. It appears to be well justified on the basis
of the 30-day mortality, and also of the experience of some
institutions. The 90-day mortality is probably a better out-
come measure, however, and the overall 20% average mor-
tality raises concern. Perhaps the conclusion should be that
patients should be selected very carefully for this approach
and that it should be done primarily in centers with suffi-
cient experience and with a documented low mortality for
right pneumonectomy after neoadjuvant therapy. The data
clearly demonstrate a strong correlation between pneumo-
nectomy mortality and center volume, as well as surgeon
specialization and a focus on noncardiac thoracic
surgery.48,49
Several additional articles are important, although they
were excluded from this review because they did not meet
criteria to be included in the analysis. These studies inde-
pendently found that a right pneumonectomy after neoadju-
vant therapy carried a higher incidence of complications
that may have contributed to a higher perioperative
mortality.15,20,50
Difference in 30-Day and 90-Day Mortalities
What is the best measure of perioperative mortality?
Traditionally, 30-day or in-hospital mortality has been cho-
sen. Most studies now, however, report only 30-day mortal-
ity. It is easier to identify the dates of surgery and of deathry c January 2012
FIGURE 4. Cause of mortality. Infectious causes of death were signifi-
cantly greater within a 30-day time frame than within a 90-day time frame
(P ¼ .012). No other statistically significant differences in the distribution
of complications for the 30-day period versus the 90-day period were ob-
served. Significant differences in causes of death were also observed within
the 90-day and 30-day periods. Asterisk indicates that the incidence of re-
spiratory complications contributing to 30-day mortality was significantly
greater than those of the infectious, cardiac, or other causes (P< .001).
Double asterisk indicates that the incidence of respiratory or other compli-
cations contributing to 90-day mortality was significantly greater than
those of infectious or cardiac causes (P<.001).
TABLE 3. Summary of 90-day mortality associated with
pneumonectomy after neoadjuvant therapy from the studies that
provided both 30-day and 90-day mortalities
Authors
Total 90-d mortality (no.)
All Right Left
Prospective randomized controlled trials
Van Schil17,19* 8/69 (11%) — —
Prospective cohort
Pezzetta26 1/34 (3%) — —
Retrospective cohort
Mansour40 7/60 (12%) 3/29 (10%) 4/31 (13%)
Refai43y 12/102 (12%) — —
Descriptive
Kim32 19/129 (15%) 13/65 (20%) 6/64 (9%)
Doddoli16,46 21/100 (21%) 14/55 (25%) 7/45 (15%)
Thibout29 21/228 (9%) — —
Martin18,20 11/97 (11%) 11/46 (24%) 0/51 (0%)
Krasna38 2/29 (7%) 2/15 (13%) 0/14 (0%)
Allen37 7/73 (10%) 5/28 (18%) 2/45 (4%)
Alifano41 13/118 (11%) — —
Average 122/1039 (12%) 48/238 (20%) 22/250 (9%)
*Unknown laterality of 1 patient. yTotal number from which analysis performed
was 77.
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It may also be true that at one time most deaths related to
a surgical procedure occurred within 30 days. With better
intensive care unit care and methods of life support, how-
ever, this may be changing. We found that 90-day mortality
appears to be a better measure to use, because it more accu-
rately captures the impact of the surgical procedure. This is
particularly true for right pneumonectomy, because the in-
crease between 30 and 90 days was not so large for the
left side.
We found that the reported 30-daymortality for a pneumo-
nectomy after neoadjuvant therapy was similar to that
reported for pneumonectomy in general.1,51 This is
corroborated by other studies that have compared mortality
of pneumonectomy with or without neoadjuvant therapy,
which have also found no difference.15,35,39,40,42-44,52 Much
sparser data are available for 90-daymortality, and it is there-
fore difficult tomake a comparison for 90-daymortalitywith
and without neoadjuvant therapy.
The mortality at 90 days is significantly higher than at
30 days in our review. Doddoli and colleagues16 suggested
that the 90-day mortality was a more accurate reflection of
the mortality associated with pneumonectomy after neoad-
juvant therapy. Although the 90-day mortality can naturally
be expected to be higher than the 30-day mortality, it is
rather surprising that the rate increased as substantially as
it did, especially for right pneumonectomy. It is not clear
whether the increase is because of neoadjuvant therapy, be-
cause of changes in cardiopulmonary function after pneu-
monectomy, or because it takes longer for complications
to lead to actual death.53-55The Journal of Thoracic and CMorbidities and Their Sequelae
Pulmonary complications were the most common cause
of death among patients undergoing neoadjuvant therapy
and pneumonectomy. It is surprising that infectious compli-
cations were not a more common cause of death, in light of
the frequent concern of bronchopleural fistula as a cause of
death after pneumonectomy.Limitations
A limitation of this review is that multiple investiga-
tors did not search and select the studies. Nevertheless,
throughout the review process, exhaustive ancillary
searches were performed to ensure that no studies were
erroneously excluded. Another limitation of this review
is that the chemotherapy regimens used among the dif-
ferent studies incorporated in this analysis were fairly
diverse. These consistently involved platinum-based ther-
apy, but there was variability in the second or third agent.
This may have accounted for the higher incidence of
complications in some studies, but this was not able to
be analyzed. Additionally, the use of adjuvant therapies
was not consistently reported, thus making it difficult
to assess the impact of this factor. Another limitation is
that no distinction could be made between a simple
and a complex pneumonectomy. The increased complex-
ity associated with an intrapericardial pneumonectomy
could have contributed to some of the morbidity andardiovascular Surgery c Volume 143, Number 1 61
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observed.CONCLUSIONS
Several conclusions can be drawn from our analysis.
When the perioperative period is extended to 90 days, how-
ever, the mortality appears to increase substantially (nearly
2-fold). In the setting of obtaining informed consent, an
explanation of the elevated risk associated with right pneu-
monectomy should be discussed. Pulmonary complications
appear to contribute the most to perioperativemortality. The
incidence of infectious complications appears to have
a greater impact on 30-day mortality than on 90-day mortal-
ity. Regarding whether a pneumonectomy should be under-
taken as part of the treatment strategy after neoadjuvant
therapy, the answer appears to be, ‘‘It depends.’’ It appears
that in general this approach is justified for a left pneumo-
nectomy; however, the mortality is high enough for a right
pneumonectomy that resection must be considered
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